Strides Q1 PAT ₹165 Cr up 57% YoY, but one-off Pivot Path gain masks flat core profit

Strides Pharma's consolidated Q1 FY27 print reads strong on the surface — revenue from operations of ₹1,265.4 Cr (+13.0% YoY, −4.4% QoQ off a seasonally heavy Q4) and reported PAT of ₹165.5 Cr, up 56.7% YoY and 28% QoQ. But nearly all of that profit jump is a one-off: a net exceptional gain of ₹63.2 Cr, driven by a ₹74.2 Cr gain on diluting the Group's Pivot Path stake to 19.95% (loss of control, fair-value remeasurement of the retained interest), partly offset by ₹11.0 Cr of product-recall/settlement charges. The year-ago quarter carried a ₹8.4 Cr exceptional loss, so the base is flattered on both ends. Stripping the one-offs, adjusted PAT is roughly ₹102 Cr versus ~₹114 Cr a year ago — down about 10%. So the honest read is +56.7% reported, ~−10% underlying.

The operating engine grew but margins lagged. Profit before exceptional items and tax rose just 5.7% YoY (₹137.7 Cr) against 13% revenue growth, so profitability trailed the topline. EBITDA margin was ~18.2% versus ~18.7% a year ago — compression, sitting mainly on cost of materials and higher employee/finance lines rather than gross margin, which held healthy at ~60.9%. The standalone entity tells the same one-off story more starkly: PAT of ₹72.9 Cr against ₹13.3 Cr a year ago, but pre-exceptional PBT was only ₹8.4 Cr — the ₹76.4 Cr Pivot Path gain is essentially the entire standalone profit.

The stock went into the print at ₹1,067.3, down 5.2% over the past month of trading.

For context: this is the second-highest quarterly PAT of the last 6 quarters.

Against management's own guidance (from the Q4 concall: EBITDA margin upwards of 20%, gross margin 58–60%, with R&D-led gains from H2 FY27, a US business target of $375–400M for FY28, and the Sandoz deal lifting branded margins from H2 FY27), the quarter is on-track but not ahead: gross margin at ~60.9% sits at the top of the guided band, while the ~18.2% EBITDA margin is running below the >20% full-year aim — consistent with the stated H2-weighting rather than a miss. There is no hard Q1 street consensus for this mid-cap; the standing analyst thesis is an FY27 PAT recovery toward ₹200+ Cr on operating leverage, which this quarter neither confirms nor refutes on an underlying basis. Concurrent board actions align with the numbers: the Pivot Path stake sale (~₹100 Cr consideration) that produced the exceptional gain, and a proposed final FY26 dividend of ₹5/share with a July 31, 2026 record date. Pharmaceutical remains the single reportable segment.